| Q41331923 | A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease |
| Q33921804 | Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease |
| Q35802571 | Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease |
| Q53313964 | Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease. |
| Q53333243 | Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. |
| Q40430983 | Clinical Pharmacokinetics of Drugs for Alzheimer's Disease |
| Q40472033 | Clinical Pharmacokinetics of Tacrine |
| Q34142818 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors |
| Q40392124 | Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease |